Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Loses Exclusivity For Generic Risperdal; Mylan To Launch Its Product

Executive Summary

Mylan is set to become the second generic manufacturer to launch a generic version of the antipsychotic drug Risperdal (risperidone), cutting short Teva's marketing exclusivity

You may also be interested in...



Teva May Have To Forfeit Exclusivity For Hyzaar/Cozaar Generics

FDA's recent wave of decisions outlining when generic firms forfeit their 180-day exclusivity appears destined to wipe out one of Teva's most prized possessions: exclusivity for Merck's Hyzaar and Cozaar

Teva May Have To Forfeit Exclusivity For Hyzaar/Cozaar Generics

FDA's recent wave of decisions outlining when generic firms forfeit their 180-day exclusivity appears destined to wipe out one of Teva's most prized possessions: exclusivity for Merck's Hyzaar and Cozaar

Generic Firms’ Ability To Seek Declaratory Judgment Limited By Federal Circuit

The Federal Circuit U.S. Court of Appeals has provided further guidance as to when generic companies can seek a declaratory judgment that they do not infringe a patent

Related Content

UsernamePublicRestriction

Register

PS050133

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel